Literature DB >> 19250248

Complete remission of cutaneous and subcutaneous melanoma metastases of the scalp with imiquimod therapy.

Giada Heber1, Doris Helbig, Iris Pönitzsch, Tino Wetzig, Wolfgang Harth, Jan-Christoph Simon.   

Abstract

Multiple cutaneous and subcutaneous melanoma metastases represent a therapeutic challenge. A 63-year-old man presented with multiple cutaneous and subcutaneous melanoma metastases on his right parieto-occipital region that appeared ten weeks after surgical excision of the primary tumor. Staging showed no further metastases. Because of the large area of cutaneous metastatic spread, the location and the limited possibility of a complete excision, we decided to begin immunomodulatory therapy with imiquimod applied for eight hours daily five days a week. After six weeks of imiquimod monotherapy, a partial remission of the cutaneous metastases had occurred. After 17 months, the remission of these metastases was complete. Four months later the patient is still free of cutaneous, visceral, cerebral and lymph node metastases.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19250248     DOI: 10.1111/j.1610-0387.2009.07038.x

Source DB:  PubMed          Journal:  J Dtsch Dermatol Ges        ISSN: 1610-0379            Impact factor:   5.584


  4 in total

1.  Advancements in unresectable melanoma: a multidisciplinary perspective.

Authors:  Mary-Kate Malecek; June K Robinson; Karl Bilimoria; Jennifer N Choi; Jaehyuk Choi; Pedram Gerami; Timothy Kruser; Timothy Kuzel; Mary Martini; Jonathan B Strauss; Jeffrey Wayne; Jeffrey Sosman; Sunandana Chandra
Journal:  Melanoma Manag       Date:  2016-08-16

Review 2.  Subcutaneous metastases from melanoma: a discussion of clinical experience.

Authors:  Piotr Rutkowski; Marcin Zdzienicki; Katarzyna Kozak
Journal:  Melanoma Manag       Date:  2014-09-05

3.  Topical TLR7 agonist imiquimod can induce immune-mediated rejection of skin metastases in patients with breast cancer.

Authors:  Sylvia Adams; Lina Kozhaya; Frank Martiniuk; Tze-Chiang Meng; Luis Chiriboga; Leonard Liebes; Tsivia Hochman; Nicholas Shuman; Deborah Axelrod; James Speyer; Yelena Novik; Amy Tiersten; Judith D Goldberg; Silvia C Formenti; Nina Bhardwaj; Derya Unutmaz; Sandra Demaria
Journal:  Clin Cancer Res       Date:  2012-07-05       Impact factor: 12.531

Review 4.  Neutralizing tumor-promoting chronic inflammation: a magic bullet?

Authors:  Lisa M Coussens; Laurence Zitvogel; A Karolina Palucka
Journal:  Science       Date:  2013-01-18       Impact factor: 47.728

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.